Mark T Iwicki
CIK 1415537 · Chief Executive Officer · last filed 2026-07-21
Mark T Iwicki is a Chief Executive Officer who has filed 85 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for QTTB, was dated Jul 21, 2026. Across all open-market trades the lifetime net is +$131.7K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $3.9K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.9K
11
85
$131.7K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QTTB | Director | — | $15.72 | — | $0 | 5 | 2026-07-21 |
| IKT | Chief Executive Officer | — | $2.30 | — | $0 | 4 | 2026-01-07 |
| Merus N.V. (MRUS) Delisted | Director | 0 | $90.00 | $0 | $0 | 8 | 2025-12-12 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Director | 0 | $54.65 | $0 | $0 | 7 | 2025-12-09 |
| KALA | Director | 2,071 | $0.65 | $1.3K | -$488.3K | 25 | 2025-10-24 |
| Third Harmonic Bio, Inc. (THRD) Delisted | Director | — | $5.38 | — | $0 | 4 | 2024-06-10 |
| Jade Biosciences, Inc. (AVTE) Delisted | Director | — | $93.80 | — | $0 | 4 | 2024-06-07 |
| PULM | Director | 1,535 | $1.68 | $2.6K | $0 | 8 | 2021-02-01 |
| COLL | Director | 0 | $35.99 | $0 | $300.0K | 7 | 2020-10-14 |
| Aimmune Therapeutics, Inc. (AIMT) Delisted | Director | 20,000 | — | — | $320.0K | 1 | 2015-08-11 |
| SEPRACOR INC /DE/ (SEPR) Delisted | EVP & Chief Commercial Officer | 122,334 | — | — | $0 | 4 | 2009-10-19 |
Recent Filings
85 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-21 | QTTB | Grant (A) | — | $0 | EDGAR |
| 2026-06-16 | QTTB | Grant (A) | — | $0 | EDGAR |
| 2026-01-07 | IKT | Grant (A) | — | $0 | EDGAR |
| 2025-12-12 | Merus N.V. (MRUS) Delisted | Mixed | −73,576 | -$7.14M | EDGAR |
| 2025-12-09 | Akero Therapeutics, Inc. (AKRO) Delisted | Disp (D) | −9,398 | $0 | EDGAR |
| 2025-10-27 | QTTB | Grant (A) | — | $0 | EDGAR |
| 2025-10-24 | KALA | Sell (S) | −154,894 | -$125.5K | EDGAR |
| 2025-10-23 | KALA | Notice (144) | −154,894 | -$125.2K | EDGAR |
| 2025-08-14 | — | Other (J) | −128,631 | $0 | |
| 2025-07-02 | IKT | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.